Tci Wealth Advisors, Inc. Allogene Therapeutics, Inc. Transaction History

Tci Wealth Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$4.92 - $8.21 $506 - $845	-103 Reduced 15.04%	582 $2,000
Q4 2022 Feb 06, 2023	SELL	$5.62 - $11.11 $5 - $11	-1 Reduced 0.15%	685 $4,000
Q3 2022 Nov 08, 2022	BUY	$10.32 - $17.28 $10 - $17	1 Added 0.15%	686 $7,000
Q1 2022 Apr 29, 2022	BUY	$7.65 - $15.29 $2,822 - $5,642	369 Added 116.77%	685 $6,000
Q4 2021 Jan 24, 2022	BUY	$13.13 - $24.52 $1,628 - $3,040	124 Added 64.58%	316 $5,000
Q3 2021 Oct 29, 2021	BUY	$21.01 - $27.64 $4,033 - $5,306	192 New	192 $5,000
Q2 2021 Aug 02, 2021	SELL	$23.49 - $35.8 $1,738 - $2,649	-74 Closed	0 $0
Q1 2021 Apr 29, 2021	BUY	$25.79 - $39.02 $1,908 - $2,887	74 New	74 $3,000

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $262M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.